• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Is there a Link Between Sickle Cell Trait and Increased Risk for Coronary Heart Disease?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • African American individuals are more likely to experience coronary heart disease and related mortality than are Non-Hispanic White individuals
    • Genetic factors such as sickle cell trait (SCT) may contribute to this unexplained excess risk
  • Hyacinth et al. (JAMA Network Open, 2021) assessed whether there is an association between SCT and the incidence of myocardial infarction (MI) or composite CHD outcomes in African American individuals

METHODS:

  • Cohort study
  • Data sources
    • Women’s Health Initiative (WHI) study (follow up 1993 and 1998 to 2014)
    • Reasons for Geographic and Racial Differences in Stroke (REGARDS) study (follow up 2003 to 2014)
    • Multi-Ethnic Study of Atherosclerosis (MESA) (follow up 2002 to 2016)
    • Jackson Heart Study (JHS) (follow up 2002 to 2015)
    • Atherosclerosis Risk in Communities (ARIC) study (follow up 1987 to 2016)
  • Participants
    • African American individuals
    • Exclusion: Sickle cell disease (homozygous for variant) or a history of CHD
  • Exposure
    • Sickle cell trait status: Determined by determining presence of rs334 (the sickle cell single nucleotide variant)
  • Study design
    • Definitions
      • MI: adjudicated nonfatal or fatal MI
      • CHD: adjudicated nonfatal MI, fatal MI, coronary revascularization procedures, or death due to CHD
    • Cox proportional hazards regression models were used to estimate the hazard ratio (HR) for incident MI or CHD comparing SCT carriers with noncarriers
    • Covariate adjustments: Age | Sex (except for the WHI study) | Study site or region of residence | Hypertension | Diabetes | Serum lipids | Global ancestry (using genome-wide genotyping data)
  • Primary outcome
    • Incident MI
    • Incident CHD

RESULTS:

  • 23,197 African American individuals
    • Women: 70.2%
    • Median age range: 53.2 to 64.0 years
    • There were no significant differences in the distribution of traditional factors associated with cardiovascular disease by SCT status within cohorts
    • Incidence of SCT: 7.7%
  • Incidence of outcomes
    • Incident MI: 1034 individuals (76 with SCT)
    • Incident CHD: 1714 individuals (137 with SCT)
  • The meta-analyzed crude incidence rate of MI did not differ by SCT status
    • With SCT: 3.8 per 1000 person-years (95% CI, 3.3 to 4.5)
    • Without SCT: 3.6 per 1000 person-years (95% CI, 2.7 to 5.1)
  • Crude incidence rate of composite CHD also did not differ by SCT status
    • With SCT: 7.3 per 1000 person-years (95% CI, 5.5 to 9.7)
    • Without SCT: 6.0 per 1000 person-years (95% CI, 4.9 to 7.4)
  • Meta-analysis of all 5 studies: SCT status was not significantly associated with either MI or composite CHD
    • MI: HR 1.03 (95% CI, 0.81 to 1.32)
    • Composite CHD: HR 1.16 (95% CI, 0.92 to 1.47)

CONCLUSION:

  • Among African American individuals, there was no link between sickle cell trait and increased risk of myocardial infarction or coronary heart disease
  • The lack of independent association was consistent between crude and adjusted data

Learn More – Primary Sources:

Association of Sickle Cell Trait With Incidence of Coronary Heart Disease Among African American Individuals

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Does Low-Dose Aspirin Reduce Risk of First Cardiovascular Events in Individuals at Moderate Risk?
Cochrane Review: Do Omega-3 Fatty Acids Reduce Cardiovascular Disease? 
The Relationship between Exercise and Heart Disease – Does Genetics Matter?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site